TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06979336: A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis

Sponsor: Genentech, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 224 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT06979336 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06979336 Rescue Dossier →